Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients With Chronic Kidney Disease and Renal Anemia.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of nephrology"
DOI: 10.1159/000531084
Abstract: Renal anemia is treated with erythropoiesis-stimulating agents (ESA), even though epoietin alfa and darbepoietin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed… read more here.
Keywords: phd inhibitors; chronic kidney; hif phd; sglt2 inhibitors ... See more keywords
Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1088288
Abstract: Diabetes mellitus (DM) is a group of metabolic diseases caused by absolute or relative deficiency of insulin secretion and characterized by chronic hyperglycemia. Its complications affect almost every tissue of the body, usually leading to… read more here.
Keywords: factor; inducible factor; hypoxia inducible; hif phd ... See more keywords